CNCE
NASDAQConcert Pharmaceuticals Inc.
Latest news
25 items- SECSEC Form 15-12G filed by Concert Pharmaceuticals Inc.15-12G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)
- SECSEC Form EFFECT filed by Concert Pharmaceuticals Inc.EFFECT - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)
- SECSEC Form EFFECT filed by Concert Pharmaceuticals Inc.EFFECT - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)
- SECSEC Form EFFECT filed by Concert Pharmaceuticals Inc.EFFECT - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)
- SECSEC Form EFFECT filed by Concert Pharmaceuticals Inc.EFFECT - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)
- SECSEC Form SC TO-T/A filed by Concert Pharmaceuticals Inc. (Amendment)SC TO-T/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
- SECSEC Form SC 14D9/A filed by Concert Pharmaceuticals Inc. (Amendment)SC 14D9/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
- INSIDERSEC Form 4: Stuart Nancy sold $50,380 worth of shares (6,048 units at $8.33) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 262,596 units (withholding obligation)4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
- INSIDERSEC Form 4: Munsie Jeffrey A sold $31,375 worth of shares (3,762 units at $8.34) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 88,049 units to cover withholding tax4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
- INSIDERSEC Form 4: Cassella James V sold $31,375 worth of shares (3,762 units at $8.34) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 173,061 units to satisfy withholding obligation4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
- INSIDERSEC Form 4: Becker Marc A. sold $31,337 worth of shares (3,762 units at $8.33) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 123,863 units (for tax liability)4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
- NEWSConcert Pharmaceuticals Says FDA Determined That Deuruxolitinib Will Maintain Its Breakthrough Therapy Designation
- PRConcert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia AreataConcert Pharmaceuticals, Inc. today announced that, after a recent review of deuruxolitinib clinical data by the U.S. Food and Drug Administration (FDA), the FDA determined that deuruxolitinib will maintain its Breakthrough Therapy designation. Deuruxolitinib, an oral Janus kinase (JAK) inhibitor, is being developed for the treatment of adult patients with moderate to severe alopecia areata. In light of the FDA approval of a different JAK inhibitor as the first treatment for alopecia areata, the FDA previously notified Concert that it was reviewing the Breakthrough Therapy designation previously granted for deuruxolitinib. At the FDA's request, Concert submitted additional clinical data an
- 13D/GSEC Form SC 13G/A filed by Concert Pharmaceuticals Inc. (Amendment)SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
- 13D/GSEC Form SC 13G/A filed by Concert Pharmaceuticals Inc. (Amendment)SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
- 13D/GSEC Form SC 13G filed by Concert Pharmaceuticals Inc.SC 13G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
- 13D/GSEC Form SC 13G filed by Concert Pharmaceuticals Inc.SC 13G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
- SECSEC Form SC 14D9 filed by Concert Pharmaceuticals Inc.SC 14D9 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
- SECSEC Form SC TO-T filed by Concert Pharmaceuticals Inc.SC TO-T - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
- SECSEC Form SC TO-C filed by Concert Pharmaceuticals Inc.SC TO-C - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
- SECSEC Form SC TO-C filed by Concert Pharmaceuticals Inc.SC TO-C - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)
- INSIDERSEC Form 4: Stuart Nancy sold $110,220 worth of shares (13,200 units at $8.35) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 268,644 units (withholding tax)4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
- INSIDERSEC Form 4: Munsie Jeffrey A sold $70,917 worth of shares (8,493 units at $8.35) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 91,811 units (for withholding tax)4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
- INSIDERSEC Form 4: Cassella James V sold $84,385 worth of shares (10,106 units at $8.35) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 176,823 units (withholding tax)4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
- INSIDERSEC Form 4: Becker Marc A. sold $70,917 worth of shares (8,493 units at $8.35) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 127,625 units (for withholding tax)4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)
CNCE FAQ
7 questionsWhat does Concert Pharmaceuticals Inc. do?
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. Its lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert Pharmaceuticals has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.Where does CNCE stock trade?
Concert Pharmaceuticals Inc. (CNCE) is listed on NASDAQ.What sector and industry is CNCE in?
Concert Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Concert Pharmaceuticals Inc. go public?
Concert Pharmaceuticals Inc. (CNCE) completed its IPO in 2014.What are analysts saying about CNCE?
Concert Pharmaceuticals Inc. has had 1 recent analyst action on file. The most recent action was from Mizuho: Buy with a $900.00 price target on 2021-10-05. Recent price targets cluster around $900.00.What companies are similar to CNCE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CNCE side-by-side with any of them on Quantisnow.How can I track CNCE on Quantisnow?
Quantisnow aggregates Concert Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CNCE to receive live email and push alerts on every new disclosure.